AKTX - Akari Therapeutics Plc

5.8
-0.200   -3.448%

Share volume: 1,575
Last Updated: 04-24-2026
Pharmaceutical Products/Pharmaceutical Preparations: -0.11%

PREVIOUS CLOSE
CHG
CHG%
$6.00
-0.20
-0.03%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
35%
Profitability 35%
Dept financing 34%
Liquidity 13%
Performance 40%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-1.19%
1 Month
4,152.20%
3 Months
2,030.79%
6 Months
630.20%
1 Year
314.29%
2 Year
389.45%
Key data
Stock price
$5.80
P/E Ratio 
0.00
DAY RANGE
$5.75 - $5.80
EPS 
$0.00
52 WEEK RANGE
$0.12 - $6.46
52 WEEK CHANGE
$314.29
MARKET CAP 
658.818 M
YIELD 
N/A
SHARES OUTSTANDING 
71.479 B
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
04-29-2025
BETA 
0.67
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$118,170
AVERAGE 30 VOLUME 
$106,210
Company detail
CEO: Rachelle Jacques
Region: US
Website: akaritx.com
Employees: 9
IPO year: 2015
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Akari Therapeutics, Plc focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities.

Recent news